Abstract
AIM: To investigate the protective effect of hesperidin (HDN) pretreatment on the expression of apoptosis-related genes in the liver of mice with acetaminophen (APAP)-induced acute liver injury.
METHODS: Sixty male Balb/c mice were randomly divided into six groups, including normal group, model group, bifendate group, low-, medium-, and high-dose HDN groups. The HDN groups were intragastrically given different doses of hesperidin for 10 d. The bifendate group was given bifendate. Acute liver injury was induced by injecting APAP in all mice except those in the normal group. After 16 h, all mice were sacrificed. Liver index was calculated. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured. The activity of superoxide dismutase (SOD) and the contents of glutathione peroxidase (GSH-PX) and malondialdehyde (MDA) in liver homogenates were determined. Pathological changes in hepatic tissue were observed under an optical microscope. Apoptosis of hepatic cells was detected by TUNEL assay. The expression of Bcl-2 and Bax mRNAs in hepatic tissue was measured by reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: Compared to the normal group, liver index, serum levels of ALT and AST, and the contents of MDA were significantly increased, and the activity of SOD and contents of GSH-PX in liver homogenates were significantly decreased in the model group (5.41% ± 0.68% vs 4.38% ± 0.17%, 1456.49 U/L ± 413.45 U/L vs 45.36 U/L ± 11.98 U/L, 1929.34 U/L ± 810.19 U/L vs 78.49 U/L ± 10.22 U/L, 32.04 nmol/mgprot ± 9.32 nmol/mgprot vs 11.83 nmol/mgprot ± 1.72 nmol/mgprot, 119.29 U/mgprot ± 33.02 U/mgprot vs 327.22 U/mgprot ± 26.66 U/mgprot, 75.89 μmol/L ± 20.21 μmol/Lvs 122.73 μmol/L ± 6.70 μmol/L, all P < 0.01). However, liver index, serum levels of ALT and AST, and the contents of MDA were significantly lower, and the activity of SOD and contents of GSH-PX were significantly higher in the bifendate group, high- and medium-dose HDN groups than in the model group (4.65% ± 0.61%, 4.59% ± 0.57%, 4.73% ± 0.63%vs 4.38% ± 0.17%; 66.36 U/L ± 13.43 U/L, 225.29 U/L ± 53.02 U/L, 773.06 U/L ± 251.27 U/L vs 1456.49 U/L ± 413.45 U/L; 105.75 U/L ± 17.02 U/L, 540.92 U/L ± 170.57 U/L, 906.78 U/L ± 226.38 U/L vs 1929.34 U/L ± 810.1 U/L; 15.74 nmol/mgprot ± 2.98 nmol/mgprot, 16.04 nmol/mgprot ± 4.92 nmol/mgprot, 20.85 nmol/mgprot ± 6.04 nmol/mgprot vs 32.04 nmol/mgprot ± 9.32 nmol/mgprot; 222.52 U/mgprot ± 56.11 U/mgprot, 245.95 U/mgprot ± 41.90 U/mgprot, 198.12 U/mgprot ± 68.09 U/mgprot vs 119.29 U/mgprot ± 33.02 U/mgprot; 108.70 μmol/L ± 25.96 μmol/L, 107.39 μmol/L ± 32.60 μmol/L, 98.90 μmol/L ± 10.71 μmol/L vs 75.89 μmol/L ± 20.21 μmol/L, all P < 0.01 or 0.05). The spleen index showed no significant differences among each group (all P > 0.05). Massive patchy necrosis surrounding the central vein, cellular swelling, massive inflammatory cell infiltration, and significant liver cell apoptosis were observed in liver tissues of mice in the model group; however, these pathological changes and cell apoptosis were significantly alleviated in the bifendate group and HDN groups. Such improvement was most obvious in the bifendate group and high-dose HDN group. APAP could significantly up-regulate Bax mRNA expression, down-regulate Bcl-2 mRNA expression, and decrease the Bcl-2/Bax ratio (0.68 ± 0.03 vs 0.28 ± 0.02, 0.21 ± 0.04 vs 0.58 ± 0.01; both P < 0.01). However, Bcl-2 mRNA expression was significantly up-regulated, Bax mRNA expression was significantly down-regulated and the Bcl-2/Bax ratio was significantly increased in the bifendate group, high- and medium-dose HDN groups (0.22 ± 0.04, 0.56 ± 0.01, 0.75 ± 0.01 vs 0.21 ± 0.04; 0.67 ± 0.06, 0.26 ± 0.005, 0.28 ± 0.02 vs 0.68 ± 0.03, all P < 0.05).
CONCLUSION: HDN pretreatment protects mice from acetaminophen-induced liver injury possibly via mechanisms associated with inhibiting lipid peroxidation and regulating the expressions of apoptosis-related genes.
Collapse